Last reviewed · How we verify
intravitreal Anti-VEGF injection
Intravitreal anti-VEGF injection blocks vascular endothelial growth factor to inhibit abnormal blood vessel growth in the eye.
Intravitreal anti-VEGF injection blocks vascular endothelial growth factor to inhibit abnormal blood vessel growth in the eye. Used for Neovascular age-related macular degeneration (wet AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO).
At a glance
| Generic name | intravitreal Anti-VEGF injection |
|---|---|
| Also known as | ranibizumab, bevacizumab, or aflibercept, Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea) |
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | VEGF inhibitor |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Anti-VEGF agents bind to and neutralize VEGF, a key signaling protein that drives pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF, these injections reduce abnormal vessel formation, decrease retinal edema, and slow or halt vision loss in conditions characterized by excessive retinal angiogenesis.
Approved indications
- Neovascular age-related macular degeneration (wet AMD)
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
- Proliferative diabetic retinopathy (PDR)
Common side effects
- Conjunctival hemorrhage
- Eye pain or discomfort
- Floaters
- Increased intraocular pressure
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL (NA)
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients (PHASE4)
- Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment (PHASE4)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PHASE3)
- Retinopathy of Prematurity - Visual Function and Retinal Structure
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: